Categories AlphaGraphs, Consumer, Earnings

BYND Earnings: Beyond Meat Q3 loss widens despite 13% revenue growth

Beyond Meat, Inc. (NASDAQ: BYND) on Wednesday reported a wider loss for the third quarter of 2021, despite a double-digit increase in revenues. The results missed Wall Street’s forecast.

Beyond Meat Q3 2021 earnings infographic

The El Segundo-based company, a pioneer in plant-based meat substitutes, reported a loss of $0.87 per share for the September quarter, on an adjusted basis, which is wider than last year’s loss of $0.28 per share. Analysts were looking for a smaller loss for the latest quarter.

The reported net loss was $54.8 million or $0.87 per share, compared to a loss of $19.3 million or $0.31 per share in the third quarter of 2020. Meanwhile, revenues increased 13% annually to $106.4 million but missed expectations.

Beyond Meat quarterly earningsrevenue trend

“Our third-quarter results reflect variability as we saw a decline from record net revenues just a quarter ago. Despite current disruptions, we remain focused on rapidly advancing key building blocks of long-term growth,” said Ethan Brown, chief executive officer of Beyond Meat.

Read management/analysts’ comments on Beyond Meat’s Q3 results

Beyond Meat’s stock lost around 19% since the beginning of 2021. The shares closed Wednesday’s session lower and dropped further in after-hours trading, following the announcement.

Prior Performance

  • Beyond Meat Q2 2021 earnings infographic

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

HP Inc. (HPQ) stock research summary | Q3 2021

HP Inc has shown a strong performance in Q4 2021. In spite of remote working, HP has shown a strong demand for PC and printer. The company has beat Zacks

VMware Inc. (VMW) stock research summary | Q3 2021

In this era of digital transformation, the technology industry is seeing a rapid influx of innovative products and solutions that help businesses adapt to the fast-changing and complex environment. VMware

IPO Alert: Cancer drug company Nuvectis Pharma set for $30-million IPO

After months of hectic activity, the IPO market experienced a lull in the Thanksgiving week, but it is still headed for a record year though the rush led by the

Add Comment
Viewing Highlight